Kamada Ltd Aktie News
6,74 $
1,25 %
heute
Nasdaq,
6. Oktober, 17:43 Uhr
tracken
Kamada Ltd Aktie News
Positiv
Seeking Alpha
●
etwa ein Monat alt
KMDA remains a buy as it delivers strong earnings growth, robust cash generation, and trades at a discount to healthcare peers with an attractive FCF yield. Q2 results confirm ongoing operating leverage, with each $1 in new sales producing $3-$5 in incremental operating profit and EBITDA margins above industry averages. Strategic growth pillars—organic expansion and infrastructure investment, i...
Neutral
Seeking Alpha
●
etwa 2 Monate alt
Kamada Ltd. (NASDAQ:KMDA ) Q2 2025 Earnings Conference Call August 13, 2025 8:30 AM ET Company Participants Amir London - Chief Executive Officer Chaime Orlev - Chief Financial Officer Conference Call Participants Annabel Eva Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division James Philip Sidoti - Sidoti & Company, LLC Brian Ritchie - Lifesci Advisors, LLC Operator Greetings, ...
Neutral
GlobeNewsWire
●
2 Monate alt
REHOVOT, Israel, and HOBOKEN, N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd.
Neutral
GlobeNewsWire
●
4 Monate alt
REHOVOT, Israel and HOBOKEN, N.J., June 17, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that, while circumstances in the Middle East are evolving, the Company is continuing the operations an...
Neutral
Seeking Alpha
●
5 Monate alt
Start Time: 08:30 January 1, 0000 8:53 AM ET Kamada Ltd. (NASDAQ:KMDA ) Q1 2025 Earnings Conference Call May 14, 2025, 08:30 AM ET Company Participants Amir London - CEO Chaime Orlev - CFO Brian Ritchie - LifeSci Advisors Conference Call Participants Annabel Samimy - Stifel James Sidoti - Sidoti & Company Operator Greetings, and welcome to the Kamada First Quarter 2025 Earnings Conference Call.
Neutral
GlobeNewsWire
●
5 Monate alt
REHOVOT, Israel and HOBOKEN, N.J., May 14, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced financial results for the three months ended March 31, 2025.
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.
